AstraZeneca PLC (AZN) は上場企業です ヘルスケア セクターの 製薬 業界で事業展開. 本社所在地は Cambridge, イギリス. 現CEOは Pascal Claude Roland Soriot.
AZN を有する IPO日 1993-05-12, 94,300 名の正社員, に上場 NYSE, 時価総額 $316.85B.
AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. The company maintains a diverse portfolio of marketed products across multiple therapeutic areas, including cardiovascular, renal, metabolic, and oncology treatments such as Tagrisso, Imfinzi, and Lynparza, alongside vaccines and rare disease medications including Vaxzevria and Soliris. AstraZeneca operates through a network of distributors and representative offices across the United Kingdom, Europe, the Americas, Asia, Africa, and Australasia, serving both primary and specialty care physicians. The company actively pursues innovation partnerships with organizations including Neurimmune AG, BenevolentAI, and Absci Corporation to advance drug discovery and development in areas such as neurodegenerative diseases, systemic lupus erythematosus, and oncology. Headquartered in Cambridge, United Kingdom, AstraZeneca was incorporated in 1992 and adopted its current name in 1999.